In the News
Becoming Aitia: why GNS shifted from AI provider to drug discoverer
CEO Colin Hill told BioCentury the company considered the shift five years ago, seeing appetite from investors and pharma partners…
read more
New Biomarkers for Atherosclerosis Found Using Digital Twins
Newly identified markers of atherosclerotic coronary artery disease (ASCAD) were pinpointed in a study using digital twins. The work was carried out by multi-omics specialist G3 Therapeutics and AI company Aitia, which has Gemini Digital Twin technology…
read more
The Milken Institute Future of Health Summit – “Is AI Just What the Doctor-or Patient-Ordered?” Panel Discussion
Watch now the panel titled “Is AI Just What the Doctor-or Patient-Ordered?” with our own Colin Hill joined by the estimated panelists at the Milken Institute Future of Health Summit 2022
read more
Intelligent Technology Brings Companies To A New Moment Of Truth
GNS Healthcare used its causal AI platform to not only predict which patients with metastatic colorectal cancer will respond to which treatments, but why…
read more
Colin Hill Opening Keynote at the Annual Merck Technology Symposium 2022
Our CEO, Colin Hill gave an opening keynote entitled “Can Virtual Patients Unlock The Biological Complexity Of Human Disease And Drive the Next Wave Of Breakthrough Drugs?” in this year annual Merck technology symposium…
read more
How AI is helping “drug hunters” succeed – GNS Co-founder, Iya Khalil talk on CNN
GNS Co-Founder Iya Khalil weighed in on how using AI and big data will transform medicine.
read more
Panel Discussion | Why the FDA will bet more on in silico simulations to trigger better success rates for NDAs
Panel Discussion at BIO conference 2022: Why the FDA will bet more on in silico simulations to trigger better success rates for NDAs.
read more
BIO 2022: Push to model disease biology advancing, but slowly
Big pharma executives and an academic ex- pert weighing the challenge at the BIO International Convention said June 14 they see another tool slowly gaining traction with the potential to decrease timelines and boost chances for approval: in silico modeling.
read more
Scrip Asks…What Does 2022 Hold For Biopharma? Part 5: Clinical Trials
Industry leaders sharing their predictions around clinical development homed in on decentralized trials, digitization and data tools as key topics for 2022…
read more
12 Tech Trends To Watch Closely In 2022
For potentially life-saving drugs and treatments, the road to commercialization is steep. Virtualizing the clinical trial is listed as a tech trend to accelerate drugs discovery and development. As per CB Insights, “In silico techniques will cut the time and money it takes to develop a drug and insulate clinical trials from disruptions…
read more